Therefore, employing more specific NFATc1 inhibitors such as NFAT-IN, or developing novel and highly specific NFATc1 inhibitors, is essential for clarifying the therapeutic potential of NFATc1 inhibition in CRC treatment. Here, CD44 is linked to colorectal carcinoma.